한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

since its establishment, eddingpharm has been committed to expanding its product line and continuously improving its competitiveness. in the early days, it represented the products of multinational pharmaceutical companies and accumulated rich market experience. however, with the changes in the industry environment, eddingpharm realized that the traditional growth model relying on the agency model was no longer sustainable. therefore, eddingpharm actively sought transformation and upgrading, and finally chose to focus on the research and development of innovative drugs and embrace a new chapter of international development.

in 2019, eddingpharm realized an important strategic layout: through two asset acquisitions, it acquired the rights to three mature products, as well as advanced manufacturing technology, global supply chain management capabilities, and key processes for complex preparations. this move not only marked the successful transformation of eddingpharm, but also laid a solid foundation for its future development.

in 2023, eddingpharm finally achieved the last breakthrough in its transformation: the launch of two innovative drugs marked the recognition of the company's r&d strength and opened a new sales peak for eddingpharm. in the fierce market competition, eddingpharm relied on continuous exploration and breakthroughs to position itself at the core needs of the chinese market, and finally formed a unique competitive advantage through precise product positioning and meticulous market analysis.

in recent years, eddingpharm has focused on the research and development of innovative drugs, actively promoted the localization of a number of original research drugs, strengthened cooperation with domestic and foreign research and development institutions, and strived to bring more and higher-quality products to chinese patients at lower prices. at the same time, eddingpharm also attaches importance to the improvement of production operations. its production company, eddingpharm (suzhou) co., ltd., was rated as a high-tech enterprise in 2023, reflecting eddingpharm's insistence on quality and efficiency.

from a traditional pharmaceutical company to a leader in innovative drugs, eddingpharm has undergone transformation and upgrading time and time again, successfully overcoming industry challenges and achieving great breakthroughs. through continuous exploration and practice, eddingpharm will become a new benchmark in china's pharmaceutical field, bringing better products and services to patients.